Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Akero Therapeutics Q2 EPS $(0.81) Beats $(0.90) Estimate; Akero's Cash, Cash Equivalents And Short And Long-term Marketable Securities As Of June 30, 2024, Were $848.3M

Author: Benzinga Newsdesk | August 09, 2024 07:25am
Akero Therapeutics (NASDAQ:AKRO) reported quarterly losses of $(0.81) per share which beat the analyst consensus estimate of $(0.90) by 10 percent. This is a 35 percent decrease over losses of $(0.60) per share from the same period last year.

Posted In: AKRO


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist